Title
Category
Credits
Event date
Cost
Reshaping the Paradigm: Implications of Recent Clinical Advances in the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) -- An ACTRIMS-ECTRIMS Virtual Satellite (Credit Expired)
$0.00
Overview:This case-based activity originally held as a satellite symposium in conjunction with MSVirtual2020 is designed to present several key analytic and diagnostic skills required to effectively characterize and treat neuromyelitis optica spectrum disorders (NMOSD). Presenting faculty work together through complex real-life cases that help to elucidate the major considerations and most common pitfalls in differentiating NMOSD from other neurodegenerative disorders such as multiple sclerosis.
How Do I…? An Integrated CME Activity Designed to Assess and Compare the Clinical Decisions of Multiple Sclerosis Specialists and General Neurologists (Credit Expired)
$0.00
Program DescriptionMultiple Sclerosis impacts nearly 1 million people in the US and is the leading cause of non-traumatic disability in adults under the age of 50. Accordingly, substantial time and energy has been dedicated to improving understanding of its biological underpinnings and subsequent therapy development. As a result, there are now 18 different disease modifying therapies available representing nine therapeutic classes with several additional options poised to join them.
Module 1: Diagnosis and Progression Monitoring
$0.00
Module 1: Diagnosis and Therapy InitiationThis module focuses on the timely and accurate diagnosis of MS through maximization of the latest technologies and strategies available. It will clarify the changes to the McDonald criteria and address the most common missteps in routine practice that currently pose risks to MS patients. 
Module 2: Initiation and Selection of Disease Modifying Therapy
$0.00
This module will focus on key clinical factors and practical considerations that may impact DMT initiation as well as utilization of the diverse agents available. Factors discussed include age, radiologic versus clinical disease activity, and usefulness of distinguishing between MS categories. It will shed light on how well long-held theories have withstood the test of time and help to provide deeper insight into how experts are approaching the contemporary management of MS.
Module 3: Navigating Controversy: Prognostic Factors, Breakthroughs, and Biomarkers
$0.00
This module will focus on topics of debate in the MS arena including best practices in DMT switching, the impact of race and pregnancy on DMT choice, and the potential role of neurofilament light (NfL) in routine practice. 
Conversations in Neurology: New Agents and Strategies for Migraine and Related Headache Disorders Edition (Credit Expired)
$0.00
Program DescriptionIt has been well documented in the medical literature that despite the prevalence of migraine throughout the US population, several diagnostic and treatment gaps exist to this day. Despite these lingering performance gaps, insights into the pathophysiology of migraine and other related headache disorders have been advancing over the past decade or so, leading to 8 new medication approvals in just the past 2 years.
From Critique to Consensus: Quantifying & Clarifying Expert Perspectives on the Future Management of Alzheimer's Disease (Credit Expired)
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
Part 1: Evolving Understanding of Pathophysiology and Modern Proposed Framework of Alzheimer’s Disease
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
Part 2: Current Treatments and Rising Phase 3 Disease-Modifying Therapies
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
Part 3: Diagnostic and Therapeutic Monitoring Strategies and their Potential Role in the Future of Disease-Modifying Therapy for Alzheimer’s Disease
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.

Pages